CAMBRIDGE, Mass.–(BUSINESS WIRE)–Triplet Therapeutics, Inc., a biotechnology company leveraging insights from the human genetics of repeat expansion disorders (REDs), announced today that co-founder, president, and CEO Nessan Bermingham, Ph.D., will speak at three upcoming virtual events:
- SunTrust Robinson Humphrey Virtual Meeting Series, Wednesday, August 5, 2020, fireside chat hosted by analyst Joon Lee, M.D., Ph.D., at 2 p.m. ET;
- William Blair BioTech Conference, Thursday, August 6, 2020, panel: “30 Years of RNA-Targeted Therapies: Where Are We Now?,” at 2 p.m. ET; and
- BTIG Virtual Biotechnology Conference, Tuesday, August 11, 2020, presentation at 11:30 a.m. ET.
Dr. Bermingham will discuss Triplet’s recent activities, including the company’s selection of its first clinical candidate from its proprietary thRED Engine™, TTX-3360, an antisense oligonucleotide with the potential to modify the course of REDs by targeting the DNA Damage Response (DDR) pathway, and its initiation of an international natural history study of Huntington’s disease, SHIELD HD.
TTX-3360, an antisense oligonucleotide, is the first clinical candidate developed from Triplet’s proprietary thRED Engine and the first clinical candidate with the potential to modify the course of repeat expansion disorders (REDs) by targeting the DNA Damage Response (DDR) pathway. A significant body of evidence supports the role of the DDR pathway as the primary driver of repeat expansion and subsequent disease onset and progression in many REDs, including Huntington’s disease (HD), myotonic dystrophy (DM1) and fragile X syndrome. Triplet is initially focusing development of TTX-3360 in HD and may also evaluate it in other central nervous system indications such as spinocerebellar ataxias (SCAs), fragile X syndrome, and familial amyotrophic lateral sclerosis (ALS).
About Triplet Therapeutics
Triplet Therapeutics is a biotechnology company developing transformational treatments for patients with repeat expansion disorders (REDs) – a group of more than 50 known genetic diseases including myotonic dystrophy type 1 (DM1), Huntington’s disease (HD), spinocerebellar ataxias (SCAs), Fragile X syndrome, and familial amyotrophic lateral sclerosis (ALS) – leveraging insights from patient genetics. Triplet designs and develops potential therapeutics for REDs using its proprietary thRED Engine, which enables the Company to develop a single oligonucleotide targeting the DNA Damage Response (DDR) pathway to potentially treat multiple REDs.
Triplet is backed by investments from Atlas Venture, MPM Capital and Pfizer Ventures, along with Invus, Partners Innovation Fund and Alexandria Venture Investments. Triplet is headquartered in Cambridge, Mass. For more information, please visit www.triplettx.com.